Cingulate Inc. Files 8-K Report

TL;DR

Cingulate Inc. filed an 8-K on 3/18/24. Check it for updates.

AI Summary

On March 18, 2024, Cingulate Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Kansas City, KS, operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing provides an update on Cingulate Inc.'s corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain information that inherently increases risk.

Key Numbers

• 001-40874 — SEC File Number (Identifies the company's filing history with the SEC.)
• 86-3825535 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Cingulate Inc. (company) — Registrant
• March 18, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Kansas City, KS (location) — Principal executive offices
• 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Mar
• $4,970,000 — ight & Co., dated January 3, 2023, from $4,970,000 to $8,470,000 and filed a prospectus su
• $8,470,000 — ted January 3, 2023, from $4,970,000 to $8,470,000 and filed a prospectus supplement (the
• $3,500,000 — the Sales Agreement for an aggregate of $3,500,000. Prior to the date hereof, the Company
• $4,969,120 — tock having an aggregate sales price of $4,969,120 under the Sales Agreement. A copy of th
• $1 — te of 173,131 shares of Common Stock to $1.13, which warrants were previously issu

Filing Documents

• form8-k.htm (8-K) — 44KB
• ex5-1.htm (EX-5.1) — 12KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• ex5-1_002.jpg (GRAPHIC) — 13KB
• 0001493152-24-010189.txt ( ) — 304KB
• cing-20240318.xsd (EX-101.SCH) — 4KB
• cing-20240318_def.xml (EX-101.DEF) — 26KB
• cing-20240318_lab.xml (EX-101.LAB) — 36KB
• cing-20240318_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events. On March 18, 2024, Cingulate Inc. (the "Company") increased the maximum aggregate offering price of the shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") issuable under the At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., dated January 3, 2023, from $4,970,000 to $8,470,000 and filed a prospectus supplement (the "Current Prospectus Supplement") under the Sales Agreement for an aggregate of $3,500,000. Prior to the date hereof, the Company sold shares of common stock having an aggregate sales price of $4,969,120 under the Sales Agreement. A copy of the legal opinion as to the legality of the $3,500,000 of shares of Common Stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto. In connection with the filing of the Current Prospectus Supplement, on March 17, 2024, the Company received a waiver from the purchaser in the Company's offering in February 2024 under the securities purchase agreement, dated February 2, 2024, by and between the Company and such purchaser. In consideration of the waiver set forth therein, the Company agreed to lower the exercise price of the Series A Warrants to purchase up to an aggregate of 346,261 shares of Common Stock and Series B Warrants to purchase up to an aggregate of 173,131 shares of Common Stock to $1.13, which warrants were previously issued by the Company to such purchaser on September 13, 2023 and to extend the exercise term of the Series A Warrants to March 17, 2029 and the term of the Series B Warrants to March 17, 2026. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Lowenstein Sandler LLP 23.1 Consent of Lowenstein Sandler LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Sec

View Full Filing

View this 8-K filing on SEC EDGAR